Treatment of Cannabis Use Disorder Among Adults with Comorbid Attention-Deficit/Hyperactivity Disorder
Medication treatment of marijuana use and Attention-Deficit/Hyperactivity disorder
Sponsor: National Institute on Drug Abuse
Enrolling: Male and Female Patients
Study Length: 13 Weeks
Clinic Visits: 25
IRB Number: 7280
U.S. Govt. ID: NCT02803229
Contact: Daniel Brooks: 212-923-3031 / brooksd@nyspi.columbia.edu
Additional Study Information: The study is an outpatient treatment study of the safety and benefit of extended-release mixed amphetamine salt (Adderall-XR) in the treatment of individuals with cannabis use disorder and Attention Deficit/Hyperactivity Disorder (ADHD). The study is a 13-week trial and requires participants to come twice per week. The primary objective of the study is to determine the safety and effectiveness of Adderall-XR in decreasing marijuana use and in promoting a decrease in ADHD symptoms.
This study is closed
Investigator
Frances Levin, MD
Do You Qualify?
Are you currently using marijuana? Yes No
Do you use marijuana at least 5 days per week? Yes No
Are you between the ages of 18 and 65? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder


CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cancel
For more information, please contact:
Daniel Brooks
brooksd@nyspi.columbia.edu
212-923-3031
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE